Dublin, Feb. 26, 2024 (GLOBE NEWSWIRE) -- The "Global Axial Spondyloarthritis Market by Type (Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA))), Drug Class (Anti-Rheumatic Drugs, Glucocorticoids, Non-steroidal anti-inflammatory Drugs (NSAIDs)), End User - Forecast 2024-2030" report has been added to ResearchAndMarkets.com's offering.
The Global Axial Spondyloarthritis Market is undergoing significant growth, with a forecasted compound annual growth rate (CAGR) of 7.42%, propelling the market from USD 5.32 billion in 2023 to an expected USD 8.79 billion by 2030. This robust expansion is a reflection of the increasing prevalence of axial spondyloarthritis, encompassing both ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), and a surge in demand for effective treatment options.
With a comprehensive FPNV Positioning Matrix and Market Share Analysis inclusive in this market study, stakeholders are equipped to evaluate vendor accomplishments and strategies with precision, thereby empowering informed decision-making. The research assesses vendors on business strategy excellence and product satisfaction, categorizing them into tailored quadrants that reflect varying degrees of market success.
The axial spondyloarthritis space is witnessing notable developments from key companies, with profiles of industry giants such as Abbott Laboratories, AbbVie Inc., Amgen Inc., Eli Lilly and Company, Novartis AG, and Pfizer Inc. being thoroughly examined to articulate their market significance.
Market Segmentation
- Type: Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
- Drug Class: Anti-Rheumatic Drugs, Glucocorticoids, Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- End User: Hospitals, Clinics, Academic Research Institutes, Rehabilitation Centers
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 180 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value (USD) in 2024 | $5.68 Billion |
| Forecasted Market Value (USD) by 2030 | $8.79 Billion |
| Compound Annual Growth Rate | 7.4% |
| Regions Covered | Global |
Companies Mentioned
- Abbott Laboratories
- AbbVie Inc.
- Amgen Inc.
- Eli Lilly and Company
- Galapagos NV
- Inmagene Biopharmaceuticals
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- UCB S.A.
For more information about this report visit https://www.researchandmarkets.com/r/3qmjv4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
